{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Y-90&page=2", "query": { "intervention": "Y-90", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Y-90&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-25T14:50:14.715Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01956812", "title": "Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Pancreatic Cancer", "Pancreatic Cancer" ], "interventions": [ { "name": "IMMU-107", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 334, "start_date": "2013-12", "completion_date": "2016-11", "has_results": false, "last_update_posted_date": "2021-08-16", "last_synced_at": "2026-09-25T14:50:14.715Z", "location_count": 42, "location_summary": "Gilbert, Arizona • Duarte, California • Long Beach, California + 33 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Norwalk", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01956812" }, { "nct_id": "NCT00372905", "title": "Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "Ibritumomab tiuxetan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2007-07-24", "completion_date": "2013-07-08", "has_results": true, "last_update_posted_date": "2019-09-04", "last_synced_at": "2026-09-25T14:50:14.715Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Chicago, Illinois", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00372905" }, { "nct_id": "NCT03516695", "title": "RadioEmbolization for the ADvancement of Y90 Glass Microspheres Registry", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Liver Cancer" ], "interventions": [ { "name": "TheraSphere®", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Boston Scientific Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 95, "start_date": "2018-02-23", "completion_date": "2018-12-12", "has_results": false, "last_update_posted_date": "2021-04-21", "last_synced_at": "2026-09-25T14:50:14.715Z", "location_count": 7, "location_summary": "Los Angeles, California • Coral Gables, Florida • Chicago, Illinois + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03516695" }, { "nct_id": "NCT00732498", "title": "Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Methylprednisolone", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "In-Zevalin", "type": "DRUG" }, { "name": "Y-Zevalin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Arizona", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2006-05-15", "completion_date": "2018-10-15", "has_results": true, "last_update_posted_date": "2019-09-04", "last_synced_at": "2026-09-25T14:50:14.715Z", "location_count": 1, "location_summary": "Tucson, Arizona", "locations": [ { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00732498" }, { "nct_id": "NCT00054834", "title": "Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non-Hodgkins Lymphoma" ], "interventions": [ { "name": "hLL2 (epratuzumab)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2003-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2021-08-16", "last_synced_at": "2026-09-25T14:50:14.715Z", "location_count": 2, "location_summary": "Philadelphia, Pennsylvania • Houston, Texas", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00054834" }, { "nct_id": "NCT00193505", "title": "Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Hodgkins Lymphoma" ], "interventions": [ { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "90Y Zevalin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2003-10", "completion_date": "2005-08", "has_results": false, "last_update_posted_date": "2011-05-03", "last_synced_at": "2026-09-25T14:50:14.715Z", "location_count": 1, "location_summary": "Nashville, Tennessee", "locations": [ { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00193505" }, { "nct_id": "NCT05953337", "title": "Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Hepatocellular Carcinoma", "Hepatocellular Carcinoma Non-resectable", "Liver Cancer" ], "interventions": [ { "name": "EYE90 Microspheres Treatment", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "ABK Biomedical", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 120, "start_date": "2023-09-21", "completion_date": "2027-02", "has_results": false, "last_update_posted_date": "2026-03-04", "last_synced_at": "2026-09-25T14:50:14.715Z", "location_count": 21, "location_summary": "Tucson, Arizona • Orange, California • Altamonte Springs, Florida + 16 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "Altamonte Springs", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05953337" }, { "nct_id": "NCT01099228", "title": "Combination Targeted Radiotherapy in Neuroendocrine Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Neuroendocrine Tumors" ], "interventions": [ { "name": "131-I MIBG and 111-In pentetreotide", "type": "OTHER" }, { "name": "131-I MIBG and In-111 DOTATATE", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "David Bushnell", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2006-09", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2016-07-21", "last_synced_at": "2026-09-25T14:50:14.715Z", "location_count": 2, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT01099228" }, { "nct_id": "NCT01359592", "title": "S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "R-CHOP regimen", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "fludeoxyglucose F 18", "type": "RADIATION" }, { "name": "selective external radiation therapy", "type": "RADIATION" }, { "name": "yttrium Y 90 ibritumomab tiuxetan", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 159, "start_date": "2011-09", "completion_date": "2023-12", "has_results": true, "last_update_posted_date": "2025-06-17", "last_synced_at": "2026-09-25T14:50:14.715Z", "location_count": 240, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Aurora, Colorado + 153 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01359592" }, { "nct_id": "NCT04390724", "title": "Optimizing Y90 Therapy for Radiation Lobectomy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HCC", "Resection", "Transplant", "Metastatic Cancer", "Adult Primary Liver Cancer" ], "interventions": [ { "name": "Y90 radioembolization", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 104, "start_date": "2020-07-17", "completion_date": "2026-11-27", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-09-25T14:50:14.715Z", "location_count": 2, "location_summary": "Jacksonville, Florida • Chicago, Illinois", "locations": [ { "city": "Jacksonville", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04390724" } ] }